Sidana, Surbhi http://orcid.org/0000-0003-3288-7614
Larson, Daniel P.
Greipp, Patricia T.
He, Rong http://orcid.org/0000-0001-6116-8163
McPhail, Ellen D.
Dispenzieri, Angela
Murray, David L.
Dasari, Surendra
Ansell, Stephen M.
Muchtar, Eli http://orcid.org/0000-0003-2210-2174
Gonsalves, Wilson I.
Kourelis, Taxiarchis V.
Ramirez-Alvarado, Marina
Kapoor, Prashant
Rajkumar, S. Vincent
Lacy, Martha Q.
Buadi, Francis K.
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Kyle, Robert A.
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
King, Rebecca L.
Gertz, Morie A.
Funding for this research was provided by:
International Waldenstrom's Macroglobulinemia Foundation (Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund, Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund)
Amyloidosis Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
International Waldenstrom's Macroglobulinemia Foundation
Article History
Received: 26 August 2019
Revised: 8 November 2019
Accepted: 17 November 2019
First Online: 28 November 2019
Compliance with ethical standards
:
: SS: Consultancy: Janssen. AD: research funding from Celgene, Takeda, Prothena, Janssen, Pfizer, Alnylam, and GSK. PK: research funding from Celgene and Takeda. MQL: research funding from Celgene. SKK: research funding and membership on an entity’s Board of Directors or advisory committees: AbbVie, Celgene, Janssen, KITE, and Merck. Membership on an entity’s Board of Directors or advisory committees: Oncopeptides and Takeda. Research funding from Novartis and Roche. MAG: honoraria/consultancy from Ionis, Alnylam, Prothena, Celgene, Janssen, Spectrum, Annexon, Apellis, Amgen, Medscape, Abbvie, Research to Practice, Physicians Education Resource, and Teva. The other authors declare that they have no conflict of interest.